Analysts Expect Curis, Inc. (CRIS) Will Post Quarterly Sales of $2.40 Million

Equities research analysts expect Curis, Inc. (NASDAQ:CRIS) to report $2.40 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Curis’ earnings. The highest sales estimate is $2.50 million and the lowest is $2.29 million. Curis reported sales of $3.26 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 26.4%. The company is scheduled to announce its next quarterly earnings results on Thursday, March 14th.

On average, analysts expect that Curis will report full-year sales of $10.19 million for the current year, with estimates ranging from $9.97 million to $10.40 million. For the next financial year, analysts forecast that the company will post sales of $10.79 million, with estimates ranging from $9.48 million to $12.10 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Curis.

Curis (NASDAQ:CRIS) last released its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.09. Curis had a negative return on equity of 299.20% and a negative net margin of 316.98%. The company had revenue of $2.85 million for the quarter, compared to analyst estimates of $2.38 million.

CRIS has been the topic of a number of analyst reports. Cowen reiterated a “buy” rating on shares of Curis in a research note on Monday, August 6th. Zacks Investment Research lowered Curis from a “buy” rating to a “hold” rating in a research note on Monday, August 13th. Finally, SunTrust Banks decreased their price objective on Curis to $8.00 and set a “buy” rating on the stock in a research note on Friday, August 3rd. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $13.33.

A number of institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC grew its position in Curis by 30.7% during the third quarter. Renaissance Technologies LLC now owns 620,729 shares of the biotechnology company’s stock worth $1,105,000 after buying an additional 145,809 shares in the last quarter. Millennium Management LLC purchased a new position in shares of Curis in the 2nd quarter worth about $540,000. Paloma Partners Management Co purchased a new position in shares of Curis in the 2nd quarter worth about $223,000. JPMorgan Chase & Co. boosted its holdings in shares of Curis by 780.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 73,954 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 65,554 shares in the last quarter. Finally, LMR Partners LLP purchased a new position in shares of Curis in the 2nd quarter worth about $124,000. Institutional investors and hedge funds own 33.03% of the company’s stock.

Shares of NASDAQ:CRIS traded down $0.06 during midday trading on Wednesday, reaching $0.86. 445,400 shares of the company traded hands, compared to its average volume of 305,940. The company has a debt-to-equity ratio of 38.74, a quick ratio of 2.63 and a current ratio of 2.63. Curis has a 12 month low of $0.81 and a 12 month high of $5.20. The firm has a market cap of $30.46 million, a price-to-earnings ratio of -0.48 and a beta of 1.16.

Curis Company Profile

Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.

Further Reading: What is the Dividend Aristocrat Index?

Get a free copy of the Zacks research report on Curis (CRIS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply